|
1
|
Ma YS, Wu TM, Lv ZW, Lu GX, Cong XL, Xie
RT, Yang HQ, Chang ZY, Sun R, Chai L, et al: High expression of
miR-105-1 positively correlates with clinical prognosis of
hepatocellular carcinoma by targeting oncogene NCOA1. Oncotarget.
8:11896–11905. 2017.PubMed/NCBI
|
|
2
|
Wu SD, Ma YS, Fang Y, Liu LL, Fu D and
Shen XZ: Role of the microenvironment in hepatocellular carcinoma
development and progression. Cancer Treat Rev. 38:218–225. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ching RHH, Sze KMF, Lau EYT, Chiu YT, Lee
JMF, Ng IOL and Lee TKW: C-terminal truncated hepatitis B virus X
protein regulates tumorigenicity, self-renewal and drug resistance
via STAT3/Nanog signaling pathway. Oncotarget. 8:23507–23516.
2017.PubMed/NCBI
|
|
4
|
Kindrat I, Tryndyak V, de Conti A,
Shpyleva S, Mudalige TK, Kobets T, Erstenyuk AM, Beland FA and
Pogribny IP: MicroRNA-152-mediated dysregulation of hepatic
transferrin receptor 1 in liver carcinogenesis. Oncotarget.
7:1276–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okajima W, Komatsu S, Ichikawa D, Miyamae
M, Kawaguchi T, Hirajima S, Ohashi T, Imamura T, Kiuchi J, Arita T,
et al: Circulating microRNA profiles in plasma: Identification of
miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma
independent of hepatic function. Oncotarget. 7:53820–53836. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng H, Zou AE, Saad MA, Wang XQ, Kwok
JG, Korrapati A, Li P, Kisseleva T, Wang-Rodriguez J and Ongkeko
WM: Alcohol-dysregulated microRNAs in hepatitis B virus-related
hepatocellular carcinoma. PLoS One. 12:e01785472017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kutay H, Bai S, Datta J, Motiwala T,
Pogribny I, Frankel W, Jacob ST and Ghoshal K: Downregulation of
miR-122 in the rodent and human hepatocellular carcinomas. J Cell
Biochem. 99:671–678. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang S, Tan G, Jiang X, Han P, Zhai B,
Dong X, Qiao H, Jiang H and Sun X: An artificial lncRNA targeting
multiple miRNAs overcomes sorafenib resistance in hepatocellular
carcinoma cells. Oncotarget. 7:73257–73269. 2016.PubMed/NCBI
|
|
9
|
Murakami Y, Yasuda T, Saigo K, Urashima T,
Toyoda H, Okanoue T and Shimotohno K: Comprehensive analysis of
microRNA expression patterns in hepatocellular carcinoma and
non-tumorous tissues. Oncogene. 25:2537–2545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ,
Cai YJ, Yang NB, Zheng MH, Dong JZ, Zhang L and Chen YP:
Hepatocellular carcinoma associated microRNA expression signature:
Integrated bioinformatics analysis, experimental validation and
clinical significance. Oncotarget. 6:25093–25108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hung CL, Yen CS, Tsai HW, Su YC and Yen
CJ: Upregulation of microRNA-19b predicts good prognosis in
patients with hepatocellular carcinoma presenting with vascular
invasion or multifocal disease. BMC Cancer. 15:6652015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng J, Zhou Z, Xu Z, Li G, Dong P, Chen
Z, Lin D, Chen B and Yu F: Serum microRNA-125a-5p, a useful
biomarker in liver diseases, correlates with disease progression.
Mol Med Rep. 12:1584–1590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jin L, Zhang Z, Li Y, He T, Hu J, Liu J,
Chen M, Gui Y, Chen Y and Lai Y: miR-125b is associated with renal
cell carcinoma cell migration, invasion and apoptosis. Oncol Lett.
13:4512–4520. 2017.PubMed/NCBI
|
|
14
|
Edge SB and Compton CC: The American Joint
Committee On Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McGlynn KA, Tsao L, Hsing AW, Devesa SS
and Fraumeni JF Jr: International trends and patterns of primary
liver cancer. Int J Cancer. 94:290–296. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dou JP, Yu J, Yang XH, Cheng ZG, Han ZY,
Liu FY, Yu XL and Liang P: Outcomes of microwave ablation for
hepatocellular carcinoma adjacent to large vessels: A propensity
score analysis. Oncotarget. 8:28758–28768. 2017.PubMed/NCBI
|
|
18
|
Chang L, Wang Y, Zhang J and Guo T: The
best strategy for HCC patients at each BCLC stage: A network
meta-analysis of observational studies. Oncotarget. 8:20418–20427.
2017.PubMed/NCBI
|
|
19
|
Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J,
Tang ZY and Zeng ZC: MicroRNA-34a expression levels in serum and
intratumoral tissue can predict bone metastasis in patients with
hepatocellular carcinoma. Oncotarget. 7:87246–87256.
2016.PubMed/NCBI
|
|
20
|
Gramantieri L, Fornari F, Callegari E,
Sabbioni S, Lanza G, Croce CM, Bolondi L and Negrini M: MicroRNA
involvement in hepatocellular carcinoma. J Cell Mol Med.
12:2189–2204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xue HY, Liu Y, Liao JZ, Lin JS, Li B, Yuan
WG, Lee RJ, Li L, Xu CR and He XX: Gold nanoparticles delivered
miR-375 for treatment of hepatocellular carcinoma. Oncotarget.
7:86675–86686. 2016.PubMed/NCBI
|
|
22
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu H, Li W, Chen C, Pei Y and Long X:
miR-335 acts as a potential tumor suppressor miRNA via
downregulating ROCK1 expression in hepatocellular carcinoma. Tumor
Biol. 36:6313–6319. 2015. View Article : Google Scholar
|
|
24
|
Scott GK, Goga A, Bhaumik D, Berger CE,
Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3
by enforced expression of micro-RNA miR-125a or miR-125b. J Biol
Chem. 282:1479–1486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dahl Cowden KD, Dahl R, Kruichak JN and
Hudson LG: The epidermal growth factor receptor responsive miR-125a
represses mesenchymal morphology in ovarian cancer cells.
Neoplasia. 11:1208–1215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cortez MA, Nicoloso MS, Shimizu M, Rossi
S, Gopisetty G, Molina JR, Carlotti C Jr, Tirapelli D, Neder L,
Brassesco MS, et al: miR-29b and miR-125a regulate podoplanin and
suppress invasion in glioblastoma. Genes Chromosomes Cancer.
49:981–990. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang L, Huang Q, Zhang S, Zhang Q, Chang
J, Qiu X and Wang E: Hsa-miR-125a-3p and hsa-miR-125a-5p are
downregulated in non-small cell lung cancer and have inverse
effects on invasion and migration of lung cancer cells. BMC Cancer.
10:3182010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hashiguchi Y, Nishida N, Mimori K, Sudo T,
Tanaka F, Shibata K, Ishii H, Mochizuki H, Hase K, Doki Y and Mori
M: Down-regulation of miR-125a-3p in human gastric cancer and its
clinicopathological significance. Int J Oncol. 40:1477–1482.
2012.PubMed/NCBI
|
|
29
|
Potenza N, Papa U, Mosca N, Zerbini F,
Nobile V and Russo A: Human microRNA hsa-miR-125a-5p interferes
with expression of hepatitis B virus surface antigen. Nucleic Acids
Res. 39:5157–5163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bi Q, Tang S, Xia L, Du R, Fan R, Gao L,
Jin J, Liang S, Chen Z and Xu G: Ectopic expression of miR-125a
inhibits the proliferation and metastasis of hepatocellular
carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang H, Li RP, Liang P, Zhou YL and Wang
GW: miR-125a inhibits the migration and invasion of liver cancer
cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol
Lett. 10:681–686. 2015.PubMed/NCBI
|
